Emmanuel Hanon (Viome)

Glax­o­SmithK­line’s head of vac­cine R&D is jump­ing to a well­ness com­pa­ny con­cen­trat­ing on the mi­cro­bio­me as re­ports of an ex­o­dus start to spread

Back in the fall of 2019, Glax­o­SmithK­line vac­cine R&D chief Em­manuel Hanon had plen­ty of good things to say about a well­ness com­pa­ny called Viome and CEO Naveen Jain. He was par­tic­u­lar­ly in­ter­est­ed in Viome’s tech­nol­o­gy for an­a­lyz­ing the gut mi­cro­bio­me and how that could in­ter­sect with new vac­cine re­search.

To­day, Hanon is jump­ing ship to join his col­lab­o­ra­tor as R&D chief as re­ports cir­cu­late of an ex­o­dus at GSK’s big vac­cine group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.